Maximizing the commercial value of personalized therapeutics and companion diagnostics-Reference-Cited by-同舟云学术

Maximizing the commercial value of personalized therapeutics and companion diagnostics

Published:2013-09 Issue:9 Volume:31 Page:803-805
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Zhang Cynthia H,Zhang Y Philip

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

http://www.nature.com/articles/nbt.2679.pdf

Reference13 articles.

1. President's Council of Advisors on Science and Technology. Priorities for personalized medicine (2008).

2. Naylor, S. & Cole, T. Overview of companion diagnostics in the pharmaceutical industry. Drug Discovery World Spring, 67–79 (2010).

3. FDA. Drug-diagnostic co-development concept paper (US Food and Drug Administration, 2004).

4. FDA. Draft guidance for industry and Food and Drug Administration staff—in vitro companion diagnostic devices (US Food and Drug Administration, 2011).

5. Ziegler, A. et al. Hum. Genet. 131, 1627–1638 (2012).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immuno-Imaging (PET/SPECT)–Quo Vadis?;Molecules;2022-05-23

2. Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression;Cancers;2020-01-23

3. Patenting nature—a comparative perspective;Journal of Law and the Biosciences;2018-10-01

4. Clinical Drug Response Prediction by Using a Lq Penalized Network-Constrained Logistic Regression Method;Cellular Physiology and Biochemistry;2018

5. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis;Expert Review of Molecular Diagnostics;2014-12-02